These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 11683694

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long-term treatment in ZE and non-ZE acid hypersecretors.
    Hirschowitz BI, Simmons J, Mohnen J.
    Aliment Pharmacol Ther; 2002 Feb; 16(2):303-13. PubMed ID: 11860414
    [Abstract] [Full Text] [Related]

  • 3. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h.
    Hirschowitz BI, Mohnen J, Shaw S.
    Aliment Pharmacol Ther; 1996 Aug; 10(4):497-506. PubMed ID: 8853753
    [Abstract] [Full Text] [Related]

  • 4. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome.
    Hirschowitz BI, Mohnen J, Shaw S.
    Aliment Pharmacol Ther; 1996 Aug; 10(4):507-22. PubMed ID: 8853754
    [Abstract] [Full Text] [Related]

  • 5. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
    Hirschowitz BI, Haber MM.
    Aliment Pharmacol Ther; 2001 Jan; 15(1):87-103. PubMed ID: 11136282
    [Abstract] [Full Text] [Related]

  • 6. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study.
    Hirschowitz BI, Simmons J, Mohnen J.
    Clin Gastroenterol Hepatol; 2005 Jan; 3(1):39-48. PubMed ID: 15645403
    [Abstract] [Full Text] [Related]

  • 7. Treatment of patients with Zollinger-Ellison syndrome.
    Mignon M, Pospai D, Forestier S, Vatier J, Vallot T.
    Clin Ther; 1993 Jan; 15 Suppl B():22-31. PubMed ID: 8205592
    [Abstract] [Full Text] [Related]

  • 8. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome.
    Metz DC, Pisegna JR, Ringham GL, Feigenbaum K, Koviack PD, Maton PN, Gardner JD, Jensen RT.
    Dig Dis Sci; 1993 Feb; 38(2):245-56. PubMed ID: 8425437
    [Abstract] [Full Text] [Related]

  • 9. [Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome].
    Mignon M, Hochlaf S, Forestier S, Ruszniewski P, Vatier J, Joubert-Collin M.
    Gastroenterol Clin Biol; 1994 Feb; 18(1):13-6. PubMed ID: 8187984
    [Abstract] [Full Text] [Related]

  • 10. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Metz DC, Forsmark C, Lew EA, Starr JA, Soffer EF, Bochenek W, Pisegna JR.
    Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
    [Abstract] [Full Text] [Related]

  • 11. A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome.
    Termanini B, Gibril F, Stewart CA, Weber HC, Jensen RT.
    Aliment Pharmacol Ther; 1996 Feb; 10(1):61-71. PubMed ID: 8871445
    [Abstract] [Full Text] [Related]

  • 12. Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole.
    Wilcox CM, Martin T, Phadnis M, Mohnen J, Worthington J, Hirschowitz BI.
    BMC Gastroenterol; 2008 May 28; 8():18. PubMed ID: 18507843
    [Abstract] [Full Text] [Related]

  • 13. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
    Ramdani A, Mignon M, Samoyeau R.
    Gastroenterol Clin Biol; 2002 Apr 28; 26(4):355-9. PubMed ID: 12070410
    [Abstract] [Full Text] [Related]

  • 14. [Effectiveness and safety of lansoprazole in the treatment of Zollinger-Ellison syndrome. First six months of treatment].
    Pospaï D, Cadiot G, Forestier S, Ruszniewski P, Coste T, Escourrou J, Mignon M, Gresze.
    Gastroenterol Clin Biol; 1998 Oct 28; 22(10):801-8. PubMed ID: 9854205
    [Abstract] [Full Text] [Related]

  • 15. Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome.
    Jensen RT, Metz DC, Koviack PD, Feigenbaum KM.
    Aliment Pharmacol Ther; 1993 Oct 28; 7 Suppl 1():41-50, discussion 61-6. PubMed ID: 8490079
    [Abstract] [Full Text] [Related]

  • 16. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion.
    Metz DC, Soffer E, Forsmark CE, Cryer B, Chey W, Bochenek W, Pisegna JR.
    Am J Gastroenterol; 2003 Feb 28; 98(2):301-7. PubMed ID: 12591045
    [Abstract] [Full Text] [Related]

  • 17. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety.
    Metz DC, Strader DB, Orbuch M, Koviack PD, Feigenbaum KM, Jensen RT.
    Aliment Pharmacol Ther; 1993 Dec 28; 7(6):597-610. PubMed ID: 8161665
    [Abstract] [Full Text] [Related]

  • 18. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome.
    Pisegna JR, Norton JA, Slimak GG, Metz DC, Maton PN, Gardner JD, Jensen RT.
    Gastroenterology; 1992 Mar 28; 102(3):767-78. PubMed ID: 1537514
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion.
    Morocutti A, Merrouche M, Bjaaland T, Humphries T, Mignon M.
    Aliment Pharmacol Ther; 2006 Nov 15; 24(10):1439-44. PubMed ID: 17081164
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.